► 7:06 Timing Discontinuation of Treatment: Critical to Maximize Chances of Successful TFR CML Content Hub @FadiHaddad_MD, of @MDAndersonNews, discusses #treatment #discontinuation in #CML.
► 0:39 Additional Chromosomal Abnormalities in CML: An Indication for Close Monitoring CML Content Hub Susanne Saussele, MD, discusses the importance of #chromosome #abnormalities in #CML.
► 0:59 FLOT2 Deficiency and Prolonged Survival in CML CML Content Hub Daniela Krause, MD, of @goetheuni, discusses #FLOT2 deficiency and #survival in #CML.
► 1:09 Selecting CML Patients Eligible for Treatment Cessation CML Content Hub Susanne Saussele, MD, discusses #treatment #discontinuation in #CML.
► 1:02 Votobatinib Promising in Phase 1/2 Trial of Mostly Heavily Pretreated CML Patients CML Content Hub @GCC_Cortes, of @GACancerCenter, discusses #votobatinib in #CML.
► 2:42 Managing Long-Term Toxicities in Pediatric CML-CP CML Content Hub Nirmalya Roy Moulik, MD, PhD, of @TataMemorial, discusses #chronic #phase #CML in #pediatric patients.
► 1:21 Managing Challenging CML Cases CML Content Hub Susanne Saussele, MD, discusses #monitoring after #treatment #discontinuation in #CML.
► 2:08 Mitochondrial Metabolism Inhibitors as a CML Treatment? CML Content Hub @VignirHelgason, of @UofGlasgow, discusses #mitochondrial #metabolic #inhibitors for #CML.
► 1:41 Risk Stratifying CML Patients for Cardiovascular Adverse Events When Choosing First-Line Therapy CML Content Hub @mjmauroMD, of @MSKCancerCenter, discusses #risk stratification and #TKI selection in #CML.
► 1:53 5-Year Results Solidify Bosutinib’s Increased Efficacy vs Imatinib CML Content Hub @GCC_Cortes of @GACancerCenter discusses #bosutinib in #CML.
